- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02198924
Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients
A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Total knee arthroplasty (TKA), though generally regarded as an effective treatment for end-stage knee OA, has been called as "one of the most painful orthopedics surgeries" due to the weight bearing characteristics of knee joint and the high demand of functional exercise within the 6-8 weeks post operation.
Parecoxib and Celecoxib have been found to be able to relieve postoperative pain, spare opioid use, improve articular function and eventually augment life quality of the patients after TKA. In China, therefore, many surgeons have accept it as a routine strategy for controlling pain post TKA to sequentially use Parecoxib and then Celecoxib. However, high quality evidence is still lacking to prove its effect on the medium or long-term functionality recovery.
This multicenter, double blind, parallel-group randomized study, therefore, is aiming to evaluate efficacy and safety of postoperative intravenous Parecoxib sodium followed by oral Celecoxib in OA patients undergoing TKA. The hypothesis is that compared to placebo with opioids as rescue treatment, sequential use of Parecoxib/Celecoxib can achieve not only less morphine consumption over postoperatively 2 weeks, but also better pain control, quicker functional recovery, and less opioid related adverse events over 6-week recovery phase.
The primary objective of this study is to evaluate the morphine-sparing effects of the combination treatment with Parecoxib and Celecoxib versus placebo in subjects undergoing TKA. The secondary objective is to compare the effects of the combination treatment versus placebo on pain relief, inflammation control and functional rehabilitation after TKA. Total 86 subjects per group would have 90% power in detecting 100 mg or more in mean difference of morphine use on Day 14 between the two groups, assuming a common standard deviation of 200, and a two-sided alpha level of 0.05. This would result in a total 172 subjects. In consideration of 30% drop outs, 246 subjects would be adequate for the study. All subjects who meet the study inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either Parecoxib/Celecoxib group or placebo group. The allocation or randomization will be study site based.Data will be collected using an Electronic Data Capture (EDC) under a strict intent-to-treat methodology, i.e., all the data of any Inform Consent Form signed subjects will be included in the study database.All subjects will be recruited from 4 study centers in China. The study will consist of 3 phases: an initial screening phase which must be completed within 30 days prior to randomization; a 6-week double blind treatment phase; and a 6 week follow up phase. A two-week wash-out procedure will be required before randomization for the patients with previous use of nonsteroidal antiinflammatory drug (NSAID) or COX-2 specific inhibitors.Variables considered continuous will be presented by descriptive statistics: number, mean, standard deviation, median, minimum, and maximum; and analyzed using parametric or non-parametric ANOVA, as appropriate. Variables considered categorical will be tabulated by frequency counts and percentages; and analyzed using Chi-square test or Fisher's exact tests. All the statistical tests will be two-sided with alpha=0.05, i.e., a p value <= 0.05 would be considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is scheduled to undergo elective unilateral total knee arthroplasty because of OA, performed under a standardized regimen of general anesthesia, as specified in this protocol.
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- The subject is a male or female over 18 years of age.
- Subjects of childbearing potential must agree to use an effective method of contraception throughout the study and for 42 days after the last dose of assigned treatment.
- Total duration of the surgical procedure is four hours or less.
- ASA grade 1-3 subjects.
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, standardized rehabilitation scheme, and other study procedures.
- The subject is in satisfactory health as determined by the investigator on the basis of medical history and physical exam.
- The subject must demonstrate sufficient psychomotor dexterity and cognitive capacity to use intravenous (IV) patient-controlled analgesia(PCA).
The subject who live near to the hospital may be considered prior for the concern of convenient and sufficient follow-up.
-
Exclusion Criteria:
- The subject requires a revision to previous knee arthroplasty and/or is having a bilateral knee arthroplasties.
- The subject requires an emergency knee arthroplasty.
- Subject uses opioids more than three days/ week prior to operation unless they discontinue the opioids two months prior to screen.
- Subject has a known hypersensitivity to COX-2 specific inhibitors, sulfonamides, lactose, NSAIDs, opioids or acetaminophen/paracetamol.
- The subject has a history of arthritis:, chronic pain, metastasis, and Paget's disease.
- The subject received any investigational medication within 30 days prior to the first dose of study medication.
- The subject has any known laboratory abnormality, which in the opinion of the investigator, would contraindicate study participation ≧1.5 times the upper limit of the normal reference range.
- The subject has an active malignancy of any type, or history of a malignancy (Subjects who have a history of basal cell carcinoma that has been successfully treated can be entered into the study.
- Subject had any condition, which could preclude use of NSAIDs or COX-2 specific inhibitors.
- The subject has active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration history.
- The subject has received warfarin or other anticoagulants during the 30 days preceding the first dose of study medication.
- Subject is anticipated to require or requires treatment with lithium.
- Subject is American Society of Anesthesiologists(ASA) grade 4-5.
- The subject has a history of a psychiatric disorder requiring new or changing treatment
- The subject has a history of uncontrolled chronic disease or a concurrent clinically significant illness, medical condition.
- The subject has any cognitive impairment or other characteristics that would in the investigator's opinion preclude study participation or compliance with protocol mandated procedures.
- Subject has a history of asthma or bronchospasm, which requires treatment with glucocorticoids.
- Subject had a history of alcohol, analgesic or narcotic abuse.
- Subject has been previously randomized into the study
- Subjects who are investigational site staff members or relatives of those site staff
- Participation in other studies within 3 months before the current study begins and/or during study participation
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
Pregnant females, breastfeeding females, or males and females of childbearing potential not using effective contraception.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Parecoxib and Celecoxib
Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery. Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3. |
Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
|
PLACEBO_COMPARATOR: placebo
Patients in the control group are supplied with the corresponding placebo with the same instructions. Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3. |
control patients are supplied with the corresponding placebo with the same instructions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total narcotic use
Time Frame: Post-operative 2 WEEKS
|
The sum of the cumulative Morphine consumption over the first 24 hours postsurgical period and the narcotic drug consumption till 72h, 2w post operation will be converted to morphine equivalents.
The converting of tramadol to Morphine equivalents is estimated as 150mg Tramadol equals to 10mg of Morphine injection.
|
Post-operative 2 WEEKS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee Society Score
Time Frame: post-operation 6 weeks
|
For more than 20 years, The Knee Society's Knee Scoring System (KSS) has served as a simple, objective way to measure a patient's functional ability before and after total knee arthroplasty (TKA).
KSS questionnaire generates three domain scores: KSS function score (walking, stairs and use of knee supports), range of motion and KSS score (pain, range of motion and stability) scores.
|
post-operation 6 weeks
|
Western Ontario and McMaster Universities Arthritis(WOMAC) Index
Time Frame: prior to operation and at 2w,4w and 6w post operation
|
The WOMAC is a widely used, proprietary set of standardized questionnaires to evaluate the condition of patients with knee osteoarthritis , including pain, stiffness, and physical functioning of the joints.
A WOMAC test takes about 12 minutes, and is among the most widely used assessments in arthritis research.
|
prior to operation and at 2w,4w and 6w post operation
|
Knee Society Score
Time Frame: prior to operation and at 2w and 4w post operation
|
For more than 20 years, The Knee Society's Knee Scoring System (KSS) has served as a simple, objective way to measure a patient's functional ability before and after total knee arthroplasty (TKA).
KSS questionnaire generates three domain scores: KSS function score (walking, stairs and use of knee supports), range of motion and KSS score (pain, range of motion and stability) scores.
|
prior to operation and at 2w and 4w post operation
|
Total Morphine use
Time Frame: over the first 24 hours postsurgical period
|
The cumulative Morphine consumption over the first 24 hours postsurgical period.
|
over the first 24 hours postsurgical period
|
Total narcotic use
Time Frame: 72h, 4w, 6w post operation
|
The cumulative Morphine consumption and opioid drug over the first 24 hours postsurgical period.
|
72h, 4w, 6w post operation
|
Visual Analogue Scale
Time Frame: prior to operation and at 24h, 48h, 72h, 2w, 4w and 6w post operation
|
A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. |
prior to operation and at 24h, 48h, 72h, 2w, 4w and 6w post operation
|
EuroQol (EQ-5D) Score
Time Frame: prior to operation and 72h, 2w, 4w and 6w post operation
|
EQ-5D is a standard instrument for use as a measure of health outcome.
EQ-5D is primarily designed for self-completion by respondents and is ideally suited for use in postal surveys, in clinics and face-to-face interviews.
It is cognitively simple, taking only a few minutes to complete.
Instructions to respondents are included in the questionnaire.
|
prior to operation and 72h, 2w, 4w and 6w post operation
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Knee circumference
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
skin temperature
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
Erythrocyte sedimentation rate(ESR)
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
C-Reactive Protein,CRP
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
interleukin-6 concentration in Synovial fluid
Time Frame: 0h, 24h and 48h post operation
|
0h, 24h and 48h post operation
|
interleukin-8 concentration in Synovial fluid
Time Frame: 0h, 24h and 48h post operation
|
0h, 24h and 48h post operation
|
interleukin-10 Synovial fluid concentration
Time Frame: 0h, 24h and 48h post operation
|
0h, 24h and 48h post operation
|
prostaglandin E2 concentration in Synovial fluid
Time Frame: 0h, 24h and 48h post operation
|
0h, 24h and 48h post operation
|
interleukin-6 concentration in Peripheral blood
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
interleukin-8 concentration in Peripheral blood
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
interleukin-10 concentration in Peripheral blood
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
prostaglandin E2 concentration in Peripheral blood
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
blood coagulation
Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation
|
prior to operation and at 72h, 2w, 4w and 6w post operation
|
The nature, incidence, duration, and severity of adverse events
Time Frame: until 6w post operation
|
until 6w post operation
|
Discontinuation due to adverse events
Time Frame: until 6w post operation
|
until 6w post operation
|
Adverse events
Time Frame: during and after trial medication discontinuation
|
during and after trial medication discontinuation
|
complete blood count
Time Frame: 2 weeks post operation
|
2 weeks post operation
|
blood chemistry parameters
Time Frame: 6w post operation
|
6w post operation
|
urinalysis test
Time Frame: 2 weeks post operation
|
2 weeks post operation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xisheng Weng, M.D., Peking Union Medical College Hospital
Publications and helpful links
General Publications
- Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, Beard DJ. Knee replacement. Lancet. 2012 Apr 7;379(9823):1331-40. doi: 10.1016/S0140-6736(11)60752-6. Epub 2012 Mar 6.
- Du Q, Ge HJ, Zhu PF. Effects of perioperative analgesia on postoperative inflammatory response. Int J Anesth Resus., 2007, 28(1):48-53.
- Holm B, Kristensen MT, Bencke J, Husted H, Kehlet H, Bandholm T. Loss of knee-extension strength is related to knee swelling after total knee arthroplasty. Arch Phys Med Rehabil. 2010 Nov;91(11):1770-6. doi: 10.1016/j.apmr.2010.07.229.
- Honsawek S, Deepaisarnsakul B, Tanavalee A, Sakdinakiattikoon M, Ngarmukos S, Preativatanyou K, Bumrungpanichthaworn P. Relationship of serum IL-6, C-reactive protein, erythrocyte sedimentation rate, and knee skin temperature after total knee arthroplasty: a prospective study. Int Orthop. 2011 Jan;35(1):31-5. doi: 10.1007/s00264-010-0973-0. Epub 2010 Feb 21. Erratum In: Int Orthop. 2011 Nov;35(11):1749.
- Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. Am J Orthop (Belle Mead NJ). 2002 Jun;31(6):336-43.
- Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth. 2003 Feb;90(2):166-72. doi: 10.1093/bja/aeg038.
- Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006 Mar;104(3):518-26. doi: 10.1097/00000542-200603000-00020.
- Zhuang Q, Tao L, Lin J, Jin J, Qian W, Bian Y, Li Y, Dong Y, Peng H, Li Y, Fan Y, Wang W, Feng B, Gao N, Sun T, Lin J, Zhang M, Yan S, Shen B, Pei F, Weng X. Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial. BMJ Open. 2020 Jan 9;10(1):e030501. doi: 10.1136/bmjopen-2019-030501. Erratum In: BMJ Open. 2020 Mar 9;10(3):e030501corr1.
- Zhuang Q, Bian Y, Wang W, Jiang J, Feng B, Sun T, Lin J, Zhang M, Yan S, Shen B, Pei F, Weng X. Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial. BMJ Open. 2016 Sep 8;6(9):e011732. doi: 10.1136/bmjopen-2016-011732.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
- Parecoxib
Other Study ID Numbers
- WI1180091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Parecoxib and Celecoxib
-
Sun Yat-sen UniversityCompletedLiver Cancer | Pain PostoperativeChina
-
Asker & Baerum HospitalCompletedRupture of Anterior Cruciate LigamentNorway
-
Chong Kun Dang PharmaceuticalCompletedOsteoarthritis HandKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersSingapore
-
Sun Yat-sen UniversityCompleted
-
Xianwei ZhangPfizerCompleted
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompletedPain, Postoperative | Laparoscopy | Anti-Inflammatory Agents, Non-SteroidalChina
-
Ministry of Health, MalaysiaUnknownUnilateral Primary Osteoarthritis of KneeMalaysia
-
First Affiliated Hospital of Harbin Medical UniversityUnknownPain, PostoperativeChina